ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 184,42
0,27%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Tenaya Therapeutics Inc (TNYA)

  7. Tenaya Therapeutics Inc (TNYA) Actualités

TNYA

Tenaya Therapeutics (TNYA)

Tenaya Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TNYA
DateHeureSourceTitreSymboleSociété
14/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
14/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
14/05/202422h05GlobeNewswire Inc.Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
02/05/202423h00GlobeNewswire Inc.Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:TNYATenaya Therapeutics Inc
18/03/202421h05GlobeNewswire Inc.Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
18/03/202413h30GlobeNewswire Inc.Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineNASDAQ:TNYATenaya Therapeutics Inc
28/02/202401h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
27/02/202422h30GlobeNewswire Inc.Tenaya Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:TNYATenaya Therapeutics Inc
26/02/202414h30GlobeNewswire Inc.Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature CommunicationsNASDAQ:TNYATenaya Therapeutics Inc
17/02/202402h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNYATenaya Therapeutics Inc
08/02/202423h25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
08/02/202414h00GlobeNewswire Inc.Tenaya Therapeutics Announces Pricing of Underwritten OfferingNASDAQ:TNYATenaya Therapeutics Inc
31/01/202422h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TNYATenaya Therapeutics Inc
03/01/202414h30GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TNYATenaya Therapeutics Inc
21/11/202322h30GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:TNYATenaya Therapeutics Inc
08/11/202322h05GlobeNewswire Inc.Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
26/10/202314h30GlobeNewswire Inc.Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
09/10/202314h30GlobeNewswire Inc.Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific MeetingNASDAQ:TNYATenaya Therapeutics Inc
05/10/202314h30GlobeNewswire Inc.Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
02/10/202323h30GlobeNewswire Inc.Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac RegenerationNASDAQ:TNYATenaya Therapeutics Inc
21/09/202322h05GlobeNewswire Inc.Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical ConferencesNASDAQ:TNYATenaya Therapeutics Inc
31/08/202322h05GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare ConferenceNASDAQ:TNYATenaya Therapeutics Inc
09/08/202322h05GlobeNewswire Inc.Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
02/08/202322h05GlobeNewswire Inc.Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth ConferenceNASDAQ:TNYATenaya Therapeutics Inc
10/05/202322h36Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TNYATenaya Therapeutics Inc
10/05/202322h29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TNYATenaya Therapeutics Inc
10/05/202322h19GlobeNewswire Inc.Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
03/05/202314h00GlobeNewswire Inc.Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual MeetingNASDAQ:TNYATenaya Therapeutics Inc
02/05/202314h43Dow Jones NewsTenaya Therapeutics Gets FDA Fast-Track Designation for TN-201NASDAQ:TNYATenaya Therapeutics Inc
02/05/202313h50GlobeNewswire Inc.Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201NASDAQ:TNYATenaya Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNYA

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
RI
Pernod Ricard
EU
ML
Michelin
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
EU
ORA
Orange
EU
RNO
Renault
COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
EU
CS
Axa
NASDAQ
GOOGL
Alphabet
EU
AI
Air Liquide
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés